A carregar...
Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease Patient
Vedolizumab is a humanized monoclonal integrin blocker with gut selective effects on lymphocyte trafficking. Its efficacy and safety for the treatment of moderate to severe Crohn’s disease and ulcerative colitis were demonstrated by phase III GEMINI studies (GEMINI 1 trial: Vedolizumab as Induction...
Na minha lista:
| Publicado no: | Cureus |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cureus
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7797417/ https://ncbi.nlm.nih.gov/pubmed/33457145 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.12582 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|